Literature DB >> 6108359

Increase of neurotensin content elicited by neuroleptics in nucleus accumbens.

S Govoni, J S Hong, H Y Yang, E Costa.   

Abstract

The content of neurotensin immunoreactive material (neurotensin-IR) of nucleus accumbens increases 16 hr after a single injection of 2 mg/kg i.p. of haloperidol; this increase persists for 8 hr or longer. Repeated injections of 2 mg/kg/day of haloperidol i.p. cause a gradual and progressive increase of neurotensin-IR. From 0.32 pmol/mg of protein, it increases to 0.57 pmol/mg (1 week) to 0.62 pmol/mg (2 weeks) and reaches 0.68 pmol/mg (3 weeks). A significant increase of neurotensin-IR content of nucleus accumbens is obtained with 0.5 mg/kg i.p. daily for 2 weeks. Maximal responses are obtained with 1 mg/kg/day in 3 weeks. The striatal neurotensin-IR content of rats injected for 2 weeks with 1 mg/kg/day of haloperidol is also increased. In these rats, the neurotensin-IR content of preoptic area hypothalamus, septum and amygdala failed to increase. The increase of neurotensin-IR material of nucleus accumbens was elicited also by chloropromazine (6 mg/kg), trifluoroperazine (2 mg/kg) and pimozide (1.5 mg/kg) while promazine (10 mg/kg) and promethazine (25 mg/kg) were ineffective. The increase of neurotensin-IR content caused by haloperidol chloropromazine, trifluoroperazine and pimozide in accumbens and striatum suggests a modulation of neurotensin metabolism, synthesis or utilization directly or indirectly through dopaminergic synapses.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6108359

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  10 in total

1.  Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain.

Authors:  D Herve; J P Tassin; J M Studler; C Dana; P Kitabgi; J P Vincent; J Glowinski; W Rostene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Proceedings of the British Pharmacological Society. 5th-7th January, 1983. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

3.  Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain.

Authors:  K B Seroogy; A Mehta; J H Fallon
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

4.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

Review 5.  How do the atypical antipsychotics work?

Authors:  J Ananth; K S Burgoyne; R Gadasalli; S Aquino
Journal:  J Psychiatry Neurosci       Date:  2001-11       Impact factor: 6.186

6.  Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics.

Authors:  K M Merchant; D M Dorsa
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

7.  Role of calcium in neurotensin-evoked enhancement in firing in mesencephalic dopamine neurons.

Authors:  Fannie St-Gelais; Mark Legault; Marie-Josée Bourque; Pierre-Paul Rompré; Louis-Eric Trudeau
Journal:  J Neurosci       Date:  2004-03-10       Impact factor: 6.167

Review 8.  Depression and antidepressants: molecular and cellular aspects.

Authors:  Cristina Lanni; Stefano Govoni; Adele Lucchelli; Cinzia Boselli
Journal:  Cell Mol Life Sci       Date:  2009-06-12       Impact factor: 9.261

Review 9.  Elucidating the role of neurotensin in the pathophysiology and management of major mental disorders.

Authors:  Mona M Boules; Paul Fredrickson; Amber M Muehlmann; Elliott Richelson
Journal:  Behav Sci (Basel)       Date:  2014-06-13

10.  Diverse roles of neurotensin agonists in the central nervous system.

Authors:  Mona Boules; Zhimin Li; Kristin Smith; Paul Fredrickson; Elliott Richelson
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-22       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.